Please tell us what you thought about today’s presentation by taking the survey below:
Alzheimer’s dementia is highly prevalent, under-diagnosed, and predicted to increase significantly in the coming decades due to an aging population. Unfortunately, a large proportion of individuals with Alzheimer’s disease (AD) also experience neuropsychiatric symptoms, such as agitation, depression, apathy, and hallucinations. In this webinar, our panelist will be reviewing the epidemiology of AD and accompanying neuropsychiatric symptoms with a focus on agitation. Dr. Jeffery Cummings will have a conversation with two individuals who have unique perspectives on the clinical presentation and experience of agitation in AD. Laurie Scherrer is an individual with early onset AD* and Roy Scherrer is a care partner. The webinar will also provide the most recent definition of agitation from the International Psychogeriatric Association (IPA) and highlight clinically validated rating scales to assess agitation in AD.
*This webinar presents one person’s individual experience with dementia and may differ from the presentation experienced by others with Alzheimer’s dementia or other dementia disorders.
Professor of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health
Individual with Early Onset Alzheimer’s Disease
Care Partner to an Individual with Early Onset Alzheimer’s Disease
Senior Long-Term Care Medical Science Liaison
Jeffrey Cummings, MD, ScD, Laurie Scherrer, and Roy Scherrer are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Mike Crooks is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Notifications
